Recent recommendations for the serological diagnosis of Lyme disease include statements on quality assurance and the use of performance panels to assess laboratory competency. We used two performance panels -one from the Centers for Disease Control and Prevention (CDC) and one from Boston Biomedica Inc. (West Bridgewater, MA) -to evaluate the sensitivity and specificity of four western blot kits. We used the same panels to compare the interpretive criteria for western blots as proposed by participants in the A repository of serum specimens from patients with Lyme Disease Mixed Titer Performance Panel can also be used well-characterized Borrelia burgdorferi infections to validate new Lyme disease antibody tests and to compare (early and late), other spirochetal infections, other the sensitivity and specificity of a newly adopted antibody test. infections and inflammatory disorders that have Each of the serum samples in the CDC panel has limited shown cross-reactivity in Lyme disease testing, and clinical classification, including presence/absence of erythema normal serum samples from areas of nonendemicity migrans (EM), culture results, and whether the patient was should be maintained by the CDC. Industry should IgG/IgM reactive or seronegative. The western blot and ELISA provide resources to develop appropriate serum panresults on this panel are not available to the purchaser until the els. These panels should be made available to retesting has been performed and sent to the CDC for analysis; search and development laboratories and to testing only then are the reference results released. Hence, use of the laboratories for validation studies. At least two such panel is blinded. While clinical characterization is provided, there are no data available on when the specimens were collected in reference to the appearance of EM or a culture positive for B. burgdorferi.
In response to numerous reports on problems associated with panels are currently available: one, which comprises a 45 -47-member panel, is available from the CDC, Lyme disease testing [1 -3] , participants in the recent Centers for Disease Control and Prevention (CDC), Association of State and the other, which comprises a 15-member mixed titer panel, is available from Boston Biomedica and Territorial Public Health Laboratory Directors (ASTPHLD) Conference on the Serological Diagnosis of Lyme (West Bridgewater, MA). Disease [4] made several recommendations including: (1) Lyme disease testing should be performed only in Materials and Methods laboratories that have comprehensive quality assurance programs.
The CDC performance panel was used to evaluate the sensi-(2) Serum samples used to evaluate screening tests or tivity and specificity of three western blot products (BBI ria, the BBICL IgG western blot is more sensitive than and as specific as the other two IgG western blot products. However, if the BBICL criteria are applied, the sensitivity of the BBICL Each assay was performed by using the procedure described IgG western blot increases to 87%, but its specificity is reduced. in the manufacturer's product literature.
The reduced sensitivities of all IgM western blot kits, particuThe BBICL criteria are:
larly those of MarDx and Cambridge Biotech, could well reflect the time at which the specimens were drawn for the panel. If IgM-significant bands -23, 39, 41, 83 kD* the patients donated §1 unit of plasma months after the initial Reactive -two of the following four bands (23, 39, 41, acute episode of Lyme disease, then the IgM titer would be 83 kD) must be present.
expected to be diminished. Equivocal -one of the following bands (23, 31, 34, 37,
The second study was also done in blinded fashion at BBICL. 39, 41, 83 kD) must be present.
IgG and IgM western blots were performed on the 46-member Nonreactive -no Lyme-specific bands are present.
CDC panel, and the results were sent to the CDC for analysis. two patients (6%). The CDC reported apparently false-negative Nonreactive -no Lyme-specific bands are present.
IgM western blots for 10 patients, all of whom were symptomThe CDC/ASTPHLD criteria are: atic. Of these 10 patients who were negative by the CDC IgM IgM-significant bands western blot and positive or equivocal by BBICL IgM western Reactive -two of the following three bands (23, 39, 41 blot, the one patient who was positive by the BBICL IgM westkD) must be present.
ern blot had confirmed EM and was culture positive for B. burgNonreactive -fewer than two bands are present.
dorferi. Of the nine patients who were negative by the CDC IgG-significant bands western blot and equivocal by the BBICL western blot, seven Reactive -five of the following bands (18, 21, 28, 30, were positive for IgG antibodies to B. burgdorferi by western 41, 45, 58, 66, 93 kD) must be present. blot in both laboratories, and two were negative for IgG antibodNonreactive -fewer than five bands are present. ies in both laboratories. All nine patients had confirmed EM and * The 83 and 93 kD bands are equivalent.
cultures positive for B. burgdorferi. Interpretive criteria for the BBICL western blot included BBICL reported that 35 of 46 patients had either positive (19 both the BBICL criteria and the CDC/ASTPHLD criteria [4] . patients) or equivocal (16 patients) IgG western blots (figure 2). The results obtained with use of the other two kits were interOf these 35 patients with clinically defined Lyme disease, 23 preted on the basis of the CDC/ASTPHLD criteria. Each blot were found to be seropositive with use of the CDC western was read independently by two technologists and then validated blot. There were 12 false-negative results. One of the specimens by a director, all of whom were employees of BBICL. Both negative for IgG by the CDC western blot but positive by the the technologists and the director were blinded as to the blot BBICL western blot was from a B. burgdorferi-infected patient manufacturer, and the specimens were coded.
whose IgM western blot was found to be positive in both laboratories. The 12 patients who were negative by the CDC/ ASTPHLD criteria but had confirmed Lyme disease were equivoResults and Discussion cal by the BBICL criteria. Seven of these B. burgdorferi-infected patients had a positive IgM western blot in both laboratories. Table 1 shows the results of our comparison of the three western blot products for detecting IgM, based on the CDC/ Four patients had a history of tick bite, EM, and positive cultures. There were no clinical data for one patient. There ASTPHLD performance panel criteria. The BBICL IgM western blot is more sensitive than either the MarDx or Cambridge were five patients who were positive by the CDC/ASTPHLD criteria and equivocal by the BBICL criteria. There were multiBiotech IgM western blot and slightly less specific than the / 9c34$$jy11 06-06-97 19:58:41 cida UC: CID ple bands on both western blots for all five of these patients, with acute Lyme disease or for those with suspected persistent disease and symptoms that are not commonly observed. We but there were not enough bands to fulfill the BBICL criteria for positivity. Thus, BBICL classified all (35) patients who recognize, however, that reduced specificity may further complicate the serodiagnosis of Lyme disease because of the potenmet the CDC criteria for Lyme disease as either positive or equivocal, while the CDC western blot results indicated that tial for increased numbers of false-positive tests. Workers at Boston Biomedica have assembled a set of 15 12 patients who met the CDC criteria for Lyme disease were negative. The case of one patient who was western blot -posialiquots of frozen serum and plasma units with reactivity to B. burgdorferi ranging from negative to strongly positive when tive for IgM at the CDC and negative for IgM with use of the BBICL western blot is still unresolved. In addition, five used with a variety of currently available test methodologies. Samples have been selected to demonstrate IgG and/or IgM specimens were equivocal with use of the BBICL IgG western blot but positive with use of the CDC IgG western blot.
reactivity. In addition, one negative plasma unit has been included as a nonreactive control. These specimens are undiluted The BBICL western blot appears to be more sensitive than the CDC western blot, the MarDx western blot, or the Camaliquots from plasma and serum units collected from 1994 to 1995. The units were processed by sterile filtration. No bridge Biotech western blot. Of course, the issue is whether a western blot should be more sensitive than specific, or vice preservatives were added. Clinical information on panel members was included when available. The purpose of this perforversa. If the western blot is to be used solely for confirmation of the results of ELISA, then specificity may be more desirable mance panel of naturally occurring serum and plasma samples is to enable manufacturers and diagnostic laboratories to evaluthan sensitivity. However, a specific western blot with low sensitivity may invalidate a sensitive and specific ELISA. A ate their tests for detection of antibodies to B. burgdorferi with characterized samples and to provide comprehensive data for highly sensitive and specific western blot is desirable for a two-tiered test system. Of major significance is the fact that comparative analysis. The tables provided in the Panel give results from both despite the CDC recommendation for two-tiered testing, many physicians who treat patients with Lyme disease do not believe commercially available test kits and in-house procedures performed at BBICL, Boston Biomedica, and internationally recthat an ELISA is an appropriate screening test and consequently use the western blot as a primary test for Lyme disease or ognized reference laboratories. Product numbers are indicated for identification of each method. Numeric results are the means request that both ELISA and western blot be done.
If the western blot is to be used in this manner, then sensitivof duplicate tests. Some results are expressed as signal-to-cutoff ratios to facilitate comparisons among kits; ratios of §1.0 are ity may be preferred over specificity, particularly for patients considered reactive. Results with use of indirect fluorescent ASTPHLD interpretive criteria to the BBICL results increased specificity but reduced sensitivity. Sample data are also proantibody are endpoint dilutions.
There are no universally accepted criteria for western blot vided from a commercially available Lyme disease antibody performance panel. Use of such a panel should enable laborainterpretation; therefore, the interpretation of the band pattern was based on the manufacturers' criteria for their kits and the tory personnel to compare results with their currently used test kits to those obtained with a wide variety of kits and methods. in-house criteria (BBICL) for the in-house methods. Figure 3 shows a representative sample of the results provided with the panel, in this case western blot results for panel members of a
